On Monday, Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY), announced its contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, which is a severe form of brain cancer.
The clinical trial, to be conducted in Spain, will recruit 30 patients from eight specialized neuro-oncology medical sites.
The trial, funded by the Medical Cannabis Bike Tour Foundation charity, represents a collaboration with renowned scientists from the Spanish Research Group of Neuro-Oncology (GEINO) and Complutense University of Madrid.
Tilray Medical agreed to provide the pharmaceutical-grade medical cannabis for the trial led by esteemed coordinating investigator Dr. Juan Manuel Sepúlveda Sánchez from GEINO.
The clinical trial is a Phase I, open-label, multicenter, intrapatient dose-escalation to evaluate the safety and ...